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Abstract
Pulmonary arterial hypertension, group 1 of the pulmonary hypertension disease family, involves pulmonary vascular remodelling,
right ventricular dysfunction and cardiac failure. Oxidative stress, through activation of mitogen-activated protein kinases is
implicated in these changes. Inhibition of apoptosis signal-regulating kinase 1, an apical mitogen-activated protein kinase, prevented
pulmonary arterial hypertension developing in rodent models. Here, we investigate apoptosis signal-regulating kinase 1 in pul-
monary arterial hypertension by examining the impact that its inhibition has on the molecular and cellular signalling in established
disease. Apoptosis signal-regulating kinase 1 inhibition was investigated in in vivo pulmonary arterial hypertension and in vitro
pulmonary hypertension models. In the in vivo model, male Sprague Dawley rats received a single subcutaneous injection of
Sugen SU5416 (20mg/kg) prior to two weeks of hypobaric hypoxia (380mmHg) followed by three weeks normoxia (Sugen/
hypoxic), then animals were either maintained for three weeks on control chow or one containing apoptosis signal-regulating
kinase 1 inhibitor (100mg/kg/day). Cardiovascular measurements were carried out. In the in vitro model, primary cultures of rat
pulmonary artery fibroblasts and rat pulmonary artery smooth muscle cells were maintained in hypoxia (5% O2) and investigated
for proliferation, migration and molecular signalling in the presence or absence of apoptosis signal-regulating kinase 1 inhibitor.
Sugen/hypoxic animals displayed significant pulmonary arterial hypertension compared to normoxic controls at eight weeks.
Apoptosis signal-regulating kinase 1 inhibitor decreased right ventricular systolic pressure to control levels and reduced muscu-
larised vessels in lung tissue. Apoptosis signal-regulating kinase 1 inhibition was found to prevent hypoxia-induced proliferation,
migration and cytokine release in rat pulmonary artery fibroblasts and also prevented rat pulmonary artery fibroblast-induced rat
pulmonary artery smooth muscle cell migration and proliferation. Apoptosis signal-regulating kinase 1 inhibition reversed pul-
monary arterial hypertension in the Sugen/hypoxic rat model. These effects may be a result of intrinsic changes in the signalling of
adventitial fibroblast.
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Introduction
Pulmonary arterial hypertension (PAH), group 1 of the pul-
monary hypertension (PH), is a multifactorial disease char-
acterised by a sustained increased mean pulmonary arterial
pressure (mPAP) 25mmHg as a consequence of pulmon-
ary vascular remodelling, infiltration of inflammatory cells,1
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thrombosis and neointima formation.2,3 These features
result in increased pulmonary vascular resistance (PVR)
and subsequent right ventricle (RV) overload, RV hypertro-
phy and eventual death. There is no cure for PAH, and
available treatments act via vasodilation and anticoagula-
tion but have limited therapeutic effect.4,5 In PAH, pulmon-
ary vascular remodelling is a result of changes in cell
hypertrophy and hyperplasia,6 apoptosis, migration and
production of extracellular matrix (ECM).2 The three
main cellular sub-types of the vascular wall, endothelial
cells (ECs), vascular smooth muscle cells and fibroblasts,7
are all implicated in PAH vessel remodelling; however, the
adventitial fibroblast is one of the first cell types activated by
vascular stressors.8–10
Oxidative stress is markedly increased in patients with
PAH and has been implicated in the changes to the pulmon-
ary vasculature and RV. These changes are thought to be as
a result of an imbalance of anti-oxidative and pro-oxidative
enzymes increasing levels of reactive oxygen species (ROS)
which can compromise vascular cell function.11–14 In animal
PAH models, elevated levels of ROS have been observed
and antioxidant agents have been shown to have beneficial
therapeutic effects.15–17 The adventitial fibroblast, in
response to environmental stresses, produces ROS leading
to phenotypic changes within the cell and are thought to
contribute to the thickening and fibrosis of the adventitia
observed in vasculopathies such as PAH.18
ROS are involved in the regulation of cell signalling path-
ways18 such as mitogen-activated protein kinase (MAPK)
pathways.19,20 MAPKs are associated with a variety of cel-
lular effects including proliferation, survival, death and
transformation.21 In vitro studies demonstrate that acute
hypoxia increases proliferation in pulmonary artery fibro-
blasts (PAFs) in a p38 MAPK-dependent response; further-
more, inhibition of p38 MAPK in rodent PAH models
prevents the disease phenotype.22 The role of ROS in
MAPK activity was demonstrated in the blockade of
MAPK activation in lipopolysaccharide (LPS)-stimulated
cells by the introduction of antioxidants23,24; furthermore,
the addition of oxidative stress mimetics induces MAPK
signalling.25
Apoptosis signal-regulating kinase 1 (ASK1) is a consti-
tutively expressed MAPK, which selectively activates the
Jun N-terminal kinase (JNK) and p38 MAPK pathways in
response to various stressors, including oxidative stress.
ASK1 is ordinarily repressed by thiol-containing thioredox-
ins; however, in instances of elevated oxidative stress, thior-
edoxin undergoes oxidation and dissociation from ASK1
leading to ASK1 activation and phosphorylation of down-
stream MAPKs.26,27 A number of studies using ASK1-
deficient mice highlight the importance of ASK1 in many
stress-related diseases.28 The possibility that small com-
pound inhibitors of ASK1 activity could ameliorate disease
development and/or progression has been demonstrated in a
study using an orally administered ASK1 inhibitor in experi-
mental PAH.29 ASK1 inhibition in this study reduced
maladaptive remodelling of the RV and pulmonary vascu-
lature, with corresponding increases in RV function and
vasoreactivity in PAH rodent models.29,30 A recent Phase
2 clinical trial (ARROW trial NCT02234141), testing a
first-in-class ASK1 inhibitor in PAH patients, however,
did not demonstrate a significant change in PVR (primary
endpoint), although no adverse side-effects were noted.31 It
is clear from the discrepancy between the pre-clinical and
clinical data that further investigation is required into the
underlying cellular mechanisms by which ASK1 inhibition
results in reduced pulmonary vascular remodelling in rodent
models. In the present study, we confirm the findings previ-
ously documented and further investigate the cellular
changes which occur.
Methods
An expanded methodology section can be found in online
Supplement.
In vivo study
All experimental procedures were carried out in accordance
with the United Kingdom Animal Procedures Act (1986),
conform to the guidelines from directive 2010/63/EU of the
European Parliament on the protection of animals used for
scientific purposes and with the ‘Guide for the Care and Use
of Laboratory Animals’ published by the US National
Institutes of Health (NIH publication No. 85-23, revised
1996). Local ethical approval was also granted.
See online Supplement for housing details, the Sugen/
hypoxic (SuHx) rat model, drug treatment and GS-444217
pharmacokinetic data. Briefly, male Sprague Dawley rats
(three weeks old) were divided into four groups. Group 1:
SuHxþV – a single subcutaneous dose of Sugen-5416
(Sigma-Aldrich, Irvine, UK) suspended in vehicle (20mg/
kg), then housed in a hypobaric chamber (atmospheric pres-
sure 550 mbar) for two weeks (weeks 0! 2) then housed at
normal room pressure (1013 mbar) for three weeks (weeks
2! 5) and given a control chow throughout (weeks 0! 8).
Group 2: SuHxþGS – as for Group 1, however, animals
received GS-444217 chow (weeks 5! 8). Group 3:
NormþV – a single subcutaneous dose of vehicle, main-
tained at normal room pressure for five weeks (weeks
0! 5) and given a control chow throughout (weeks
0! 8). Group 4: NormþGS – as for Group 3, however,
animals received GS-444217 chow (weeks 5! 8) (sum-
marised in online Supplemental Fig. 1). Animals were
weighed at the end of the study.
Haemodynamic measurements. Haemodynamic measurements
were obtained in a cohort of animals at five weeks and
another cohort of animals at eight weeks. Animals were
anaesthetically induced by inhalation in 3% (v/v) isoflurane
and then maintained at 1.5–2% (v/v) isoflurane
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supplemented with a constant flow of 5% (v/v) oxygen.
Haemodynamic measurements were taken using an ultra-
miniature polyimide nylon catheter (SPR-869NR, Millar,
Houston, TX, USA) as per the manufacturer’s instructions
with the PowerLab 35 Series data acquisition system and
LabChart Pro (AD instruments, Oxford, UK) using the
pressure volume (PV) Loop analysis module. The catheter
was inserted into the jugular vein and guided into the RV of
the heart to measure right ventricular systolic pressure
(RVSP). After RVSP was determined, the carotid artery
was isolated and the same catheter was inserted to determine
systolic arterial pressure (SAP). The PV loop system also
generated heart rate and cardiac output (CO) data. On
removal of the catheter, blood was collected immediately
to obtain both serum and plasma fractions, these were
used for further analysis by enzyme-linked immunosorbent
assay (ELISA). Subsequently, animals were euthanized by
terminal anaesthesia through inhalation overdose 5% (v/v)
isoflurane with a constant flow of 5% (v/v) oxygen until
cessation of breathing as approved by the local ethics
committee.
Right ventricular hypertrophy and tissue harvest. Immediately fol-
lowing hemodynamic assessment, animals were culled and
tissues were harvested for further analysis. The heart and
lungs were flushed with ice-cold phosphate buffered saline
(PBS) at a low pressure using a blunt needle to clear periph-
eral blood cells. The right lung was tied off with suture and
excised for molecular analysis. In a cohort of animals from
each group, the hearts were isolated, atria removed and
separated to give RV and left ventricle (LV). These were
weighed separately and right ventricular hypertrophy
(RVH) was assessed by the Fulton Index ((dry weight of
the RV)/(dry weight of the LVþ septum)). In the remaining
animals from each group, the heart was excised whole and
fixed with 10% (v/v) neutral buffered formalin (NBF) for
48 h under mild agitation before paraffin processing and
embedding for immunohistological analysis. Large pulmon-
ary arteries (PAs) were dissected for rat pulmonary artery
fibroblasts (RPAFs) isolation and the left lung was inflated
and fixed with 10% (v/v) NBF as for hearts.
Immunohistology. 5 mm lung and heart sections were cut, from
paraffin blocks and mounted on Superfrost microscope
slides (Sigma-Aldrich, Irvine, UK).
Vascular thickening was determined by smooth muscle
actin antibody (ab5694, Abcam, Cambridge, UK) staining,
thickening was characterised by an increase in the vessel wall
diameter of more than 50% of the arterial wall or complete
occlusion. The number of remodelled vessels over the total
number of vessels present in a lung section was determined.
Sections were analysed in a blinded manner.
Heart sections were stained using a common regressive
Haemotoxylin and Eosin (H&E) staining methodology to
determine gross morphology and cardiomyocyte cross-
sectional area. High-power images of five areas randomly
distributed across ventricles were analysed by ImageJ soft-
ware. Mean cardiomyocyte size was determined by measur-
ing the cross sectional area of minimally 20 transversally cut
cardiomyocytes at the level of the nucleus.
Picro-sirius red staining was used for analysis of cardiac
fibrosis using a Picro-sirius red staining kit (Abcam,
Cambridge, UK) as per manufacturer’s instructions. High-
power images were acquired of five random areas per ven-
tricle. Using ImageJ IHC tool, the percentage tissue area
positive for collagen (pink) was determined.
In vitro study
Primary cell culture and exposure to hypoxia. RPAFs and rat pul-
monary artery smooth muscle cells (RPASMCs) were pro-
duced by primary cell culture of PAs dissected free from the
lung andheart of adultmale SpragueDawley rats (eitherwild-
type animals or those which were part of the in vivo study).
Tissue was manually manipulated to culture either RPAFs or
RPASMCs using an adaption of the explant technique by
Freshney32 and summarised in online Supplement. Cells
were maintained under standard culture conditions33 in the
presence of serum or were exposed to hypoxia as an in vitro
model of PH by incubation in a variable O2 humidified tem-
perature-controlled chamber (5% CO2 in air at 37
C) with a
PO2 maintained at 35mmHg.
33 All cellular experiments are
carried out as biological replicates.
RPASMC culture in RPAF conditioned media. RPAF were cultured
until 80% confluent and quiesced in serum-free Dulbecco’s
Modified Eagle’s Medium (DMEM) for 24 h before being
cultured in hypoxic or normoxic culture conditions (as
above) for 24 h whereby culture media (CM) was collected.
RPASMC were cultured until 50–60% confluence then
quiesced for 24 h in serum free media. Media was aspirated
from cells and RPAF CM was added to each well for further
analysis in the presence or absence of GS-444217.
RPAF and RPASMC co-culture. RPAFs were seeded in 12-well
inserts (ThinCertTM, Greiner Bio-One, Stonehouse, UK).
RPASMCs were cultured in 12-well plates and at 50–60%
confluence, then quiesced for 24 h. RPAF inserts were trans-
ferred into the RPASMC-containing wells, cells were cul-
tured with and without GS-444217 in either normoxic or
hypoxic conditions, RPAF inserts were removed prior to
analysis.
Cell proliferation. RPAF were grown in 24-well culture plates
in normal culture conditions (as above) until 60% confluent.
Cells were quiesced in serum-free DMEM for 24 h then cul-
tured under normoxic or hypoxic conditions in the presence
or absence of varying concentrations of serum for 24 h with
or without the ASK1 inhibitor. Two methods of cell count-
ing were used, [3H] thymidine incorporation and automated
cell counter, and comparable results were obtained (proto-
cols are summarised in online Supplement).
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Cell migration. The ‘scratch’ assay was used to determine cell
migration over a 24-h period following cellular manipula-
tion (further detail in online Supplement).
Preparation of GS-444217. GS-444217, a potent and selective
small-molecule inhibitor of ASK1, was synthesised by
Gilead Sciences Inc. (Foster City, USA) and was reconsti-
tuted in low percentage (<0.1%) dimethyl sulphoxide and
suspended in DMEM. The ASK1 inhibitor was used
throughout at a concentration of 1 mM.
Protein analysis
Protein abundance in tissue homogenate and RPAFs was
determined by immunoblotting, densitometry and normal-
ised to total p38 MAPK as housekeeper/loading control as
described in online Supplement.
Enzyme-linked immunosorbent assays
ELISAs were carried out to quantify the levels of key cyto-
kines. These included rat soluble intracellular adhesion mol-
ecule 1 (sICAM-1), rat tissue inhibitor of metalloproteinases
1 (TIMP-1) (both from R&D Systems) and Endothelin-1
(ET-1) (Enzo Life Sciences, Exeter, UK), all ELISAs were
carried out as per manufacturer’s instructions.
Statistical analysis
In vivo experiments are n¼ 4–6 per experimental group and
in vitro experiments were n¼ 3–6 unless otherwise stated.
Data are expressed as means standard error of the mean.
Treatments were compared by one-way or two-way repeated
measures analysis of variance with appropriate post hoc
tests highlighted in relevant text. A p value <0.05 was con-
sidered statistically significant.
Results
ASK1 inhibition reverses cardiopulmonary parameters
associated with PH in the SuHx rat model
At eight weeks, RVSP was raised in the SuHxþV group
compared to NormþGS and SuHxþGS (46.68
6.51mmHg vs 29.59 1.26 and 25.18 2.97mmHg respect-
ively) (Fig. 1a)). While body weight was found to be
decreased in SuHx groups, neither SuHx nor ASK1 inhibi-
tor altered any other cardiac parameters measured (SAP
heart rate and CO) (Fig 1b–e). The SuHxþV group dis-
played significantly greater RV hypertrophy compared to
the NormþV; the addition of GS-444217 did not signifi-
cantly reduce RV hypertrophy (Fig. 1f). Morphologically,
SuHxþV hearts appeared to have considerable RV free
wall thickening which was not observed in any other
groups (as highlighted on histological images; Figs 1g–j).
Cardiomyocyte area, as determined by mean cell area
(Pixels) of high magnification images of H&E-stained
heart sections (Fig. 1k), was found to be significantly
increased in the SuHxþV group compared to all other
groups with SuHxþGS comparable to both NormþV
and NormþGS (Fig. 1l). RV fibrosis as determined by
Picro-sirius red stain (Fig. 1m) highlighted more fibrosis
(Picro-sirius positive area) in the SuHxþV group compared
to all other groups (Fig. 1n).
Alpha smooth muscle actin staining was carried out on
lung sections to determine pulmonary vascular remodelling
(Fig. 2a), this stain highlighted a greater number of remo-
delled vessels in the SuHxþV group compared to both
Norm groups, the addition of GS-444217 in the
SuHxþGS group prevented this rise (Fig. 2b).
Phospho-p38 MAPK (pp38 MAPK) protein abundance
in whole tissue homogenate was determined by Western blot
analysis. An increase in pp38 MAPK relative abundance
was observed in lung homogenate from SuHxþV animals
compared to NormþV, NormþGS and SuHxþGS
(Fig. 2c). In the right ventricular tissue homogenates, there
was a rise in the abundance of pp38 MAPK levels in
SuHxþV animals compared to both normoxic groups,
while a reduction was noted in SuHxþGS, this was not
found to be statistically significant (Fig. 2d). No detectable
difference in pp38 MAPK was determined in LV tissue hom-
ogenates (Fig. 2e). Phospho-ASK1 (pASK1) was also inves-
tigated by Western blot and demonstrated a significant
increase in abundance in the lung of SuHxþV compared
to NormþGS and SuHxþGS lung tissue ((Fig. 2f) similar
observations were noted in LV and RV – data not shown).
Plasma from all groups was analysed for potential bio-
markers. Circulating ET-1 was significantly raised in
SuHxþV animals compared to SuHxþGS (Fig. 2g).
Similarly, in SuHxþV animals, circulating TIMP-1 was sig-
nificantly raised compared to all other groups, SuHxþGS
was comparable to both normoxic groups (Fig. 2h).
Circulating levels of B-type natriuretic peptide (BNP) were
also significantly raised in SuHxþV animals compared to
NormþV controls. In the presence of GS-444217, BNP
levels were comparable to controls (NormþV and
NormþGS) with a trend towards significant reduction
compared to SuHxþV (p¼ 0.055 (Fig. 2i)).
ASK1 inhibitor prevents remodelling features in RPAF cells
cultured from the SuHx rat model
RPAFs were cultured from isolated PAs from either
NormþV, SuHxþV or SuHxþGS animals and
were then investigated further. Using a scratch assay, the
migratory capacity of these RPAFs cultured with differ-
ing concentrations of serum was investigated. SuHxþV
and SuHxþGS were found to have significantly
greater migration to NormþV cells at all three serum con-
centrations. SuHxþGS cells were also found to migrate
significantly less than SuHxþV cells (Fig. 3a) at all serum
levels.
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Fig. 1. Sugen/hypoxic rat haemodynamic and cardiac characteristics after ASK1 inhibition. The impact of ASK1 inhibitor GS-44217 in reversing
established pulmonary hypertension (PH) was investigated in the Sugen/hypoxic (SuHx) rat model. Four groups of animals were investigated;
SuHx animals treated with vehicle (SuHxþV) or the ASK1 inhibitor GS-444217 (SuHxþGS) for three weeks post disease establishment (at five
weeks) or age-matched normoxic controls treated with vehicle (NormþV) or drug (NormþGS). Parameters investigated were (a) right
ventricular systolic pressure (RVSP), (b) body weight, (c) systemic arterial pressure (SAP), (d) heart rate, (e) cardiac output, (f) right ventricular
hypertrophy, (g–j) representative images of transverse heart histological sections stained with haematoxylin (double arrows highlight RV free wall
thickening), (k) cardiomyocyte cross-sectional area determined from high-powered magnification images of haematoxylin-stained transverse
whole heart sections and (l) quantification by post hoc ImageJ analysis, (m) collagen content determined in heart sections stained with Picro-sirius
red stain and (n) quantification by post hoc ImageJ analysis. Data are (a, c, d and f) n¼ 6 animals per group (b) n¼ 7/8 animals per group, (e) n¼ 4
animals per group, displayed as individual data points and mean; (l and n) n¼ 6 animals (mean of four sections per heart) displayed as individual
data points and mean (l) or mean SEM (n). Statistical analysis is by two-way ANOVA with Turkey’s post hoc analysis *p 0.05 and **p 0.01,
***p 0.001.
RV: right ventricle; LV: left ventricle.
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Fig. 2. Sugen/hypoxic rat cardiopulmonary cardiac characteristics after ASK1 inhibition. The impact of ASK1 inhibitor GS-44217 in reversing
established pulmonary hypertension (PH) was investigated in the Sugen/hypoxic (SuHx) rat model. Four groups of animals were investigated;
SuHx animals treated with vehicle (SuHxþV) or ASK1 inhibitor GS-444217 (SuHxþGS) for three weeks post disease establishment (at five
weeks) or age-matched normoxic controls treated with vehicle (NormþV) or drug (NormþGS). (a) Pulmonary vascular remodelling was
investigated through analysis of high-power magnification images of lung alpha smooth muscle actin (a-SMA) immunohistochemistry, arrows show
pulmonary vessels of interest and (b) and pulmonary vascular remodelling quantification. (c–f) Protein abundance determined and quantified by
Western blot analysis in tissue homogenate for phospho p38 MAPK (pp38 MAPK) in (c) lung, (d) right ventricle (RV), (e) left ventricle (LV) and
(f) phospho ASK1 (pASK1) in lung. All protein abundance is normalised to total p38 MAPK (tp38 MAPK) and is presented as relative abundance
(AU). Data are n¼ 4 biological replicates per group and are displayed as mean SEM analysed by one-way ANOVA with Turkey’s post hoc
analysis. *p 0.05. Plasma analysis was also carried out to quantify the levels of (g) endothelin-1 (ET-1), (h) tissue inhibitor of metalloproteinases
(TIMP1) and (i) B-type natriuretic peptide (BNP). Quantification data is n¼ 5 per group for all plasma analyses and displayed as individual data
points with mean. Statistical analysis is by one-way ANOVA with Turkey’s post hoc analysis *p 0.05 and **p 0.01.
MAPK: mitogen-activated protein kinase; ASK1: apoptosis signal-regulating kinase 1.
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Cell proliferation was investigated following the addition
of serum. No significant difference in cell proliferation was
noted between cells at 0 and 1% serum; however, at 5%
serum, a significant rise in proliferation was noted
in SuHxþV cells compared to both NormþV and
SuHxþGS cells (Fig. 3b).
RPAF cells were further investigated at increasing serum
concentrations to determine pp38 MAPK abundance by
Western blot (Fig. 3c). A rise in pp38 MAPK was observed
in each group with increasing serum levels; when comparing
the groups at a given serum concentration, the levels were
significantly lower for SuHxþGS cells compared to
SuHxþV (1% serum 65.47 31.01 vs 319.58 68.34
abundance AU; 5% 191.43 59.83 vs 469.07 45.41 AU,
Fig. 3d).
Conditioned media from cells from all three groups main-
tained either in normoxia or hypoxia for 24 h was investi-
gated by ET-1 ELISA. It was observed that in normoxic
conditions, cells from the SuHxþV animals produced sig-
nificantly more ET-1 than cells from NormþV animals
(56.12 9.94 vs 33.32 5.09 pg/mL) and that cells from
SuHxþGS animals had significantly lower levels of ET-1
than NormþV. Similarly, cells which were incubated in
hypoxic conditions demonstrated the same pattern of ET-1
levels; however, values were raised compared to normoxia
(Fig. 3e).
Fig. 3. Phenotypic characteristics of study animal cells. Rat pulmonary artery fibroblasts (RPAFs) were cultured from SuHx animals treated with
vehicle (SuHxþV) or GS-444217 (SuHxþGS) or normoxic controls. (a) Cellular migration was investigated in each group following incubation
with varying but sub-proliferative concentrations of serum and was determined using scratch assay then quantified as percent gap closure. (b)
Proliferation was investigated in each group following incubation with varying but pro-proliferative concentrations of serum and was determined
using an automated cell counter and displayed as cell number. (c and d) Phospho p38 mitogen-activated protein kinase (pp38 MAPK) protein
abundance was determined in cells with varying concentrations of serum by Western blot and graphically displayed relative to total p38 MAPK
(tp38 MAPK) levels. (e) Cell culture conditioned media analysis was also carried out to quantify the levels of endothelin-1 (ET-1) from RPAFs
cultured from experimental animals maintained in normoxic or hypoxic culture conditions. Data are n¼ 4 and represented as mean SEM, and
are analysed by two-way ANOVA and Tukey’s post hoc analysis. *p 0.05, **p 0.01 and ***p 0.001.
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ASK1 inhibitor alters signalling pathways of wild-type
RPAFs in an in vitro model of PH
A significant increase in hypoxia-inducible factor (HIF)-1a,
pASK1, extracellular signal-regulated kinase 1/2 (ERK1/2)
and pp38 MAPK protein abundance was observed in hyp-
oxic cells both in the presence or the absence of 1% serum
when compared to cells grown in normoxia. These increases
in abundance were not observed in cells which were pre-
incubated with the ASK1 inhibitor GS-444217. The relative
abundance of phospho-mitogen activated- kinase kinase 3/6
(pMKK3/6) and pJNK were also investigated; however,
there was no change in levels detected in cells which were
cultured in hypoxic conditions with or without serum (Fig.
4a–g). Cytokine levels were studied in RPAF CM using
ELISAs. sICAM-1 levels were increased in hypoxic cells
compared to normoxic cells and with the addition of
ASK1 inhibitor; levels were comparable to controls (Fig.
4h). Hypoxic conditions had no impact on the detectable
levels of TIMP-1 in CM; the addition of serum, however,
did significantly increase levels which were prevented by the
addition of GS-444217 (Fig. 4i). RPAFs cultured in hypoxia
displayed increased levels of ET-1, however, in the presence
of GS-444217. ET-1 levels in the hypoxic cells were reduced
to levels comparable to normoxic controls (Fig. 4j).
ASK1 inhibitor prevents remodelling characteristics of
wild-type RPAFs in an in vitro model of PH
In an in vitro model of PH-acute hypoxia, wild-type RPAF
displayed increased proliferation compared to normoxia
which GS-444217 prevented, with a four-fold reduction
in proliferation to levels reaching that of normoxic cells
(Fig. 5a). GS-444217 had no effect on wild-type RPASMC
proliferation in either normoxic or hypoxic conditions
(Fig. 5b). RPASMCs co-cultured with RPAF and main-
tained in normoxia (Norm CC) displayed no detectable dif-
ference in proliferation; however, a significant increase was
noted when co-cultured with RPAF in hypoxic conditions.
GS-444217 reduced this proliferation by 50%. There was
no change in the proliferative response of RPASMCs cul-
tured in normoxic RPAF CM (Norm CM); however,
increased proliferation was noted in hypoxic RPAF CM
(Hyp CM). GS-444217 had no effect on CM-mediated
RPASMC proliferation (Fig. 5d).
GS-444217 did not affect RPAF migration under
normoxic conditions (Fig. 5e); however, in hypoxic cells, a sig-
nificant increase in migration was observed, the addition of
GS-444217 prevented migration. In RPASMC, incubation of
GS-444217 had no effect on migration in normoxic or hyp-
oxic cells (Fig. 5f). RPASMC with Hyp CC displayed an
enhanced migratory response, compared to RPASMC cul-
tured alone, which was prevented by GS-444217 (Fig. 5g).
RPASMCs cultured in Hyp CM displayed enhanced migra-
tion compared to Norm CM. The addition of GS-444217 did
not prevent scratch closure (Fig. 5h).
To determine whether ET-1 mediated RPASMC pheno-
typic changes, cells were incubated with increasing concen-
trations of ET-1 and were then assessed for proliferative and
migratory capacity. First, it was determined that ET-1 was
capable of increasing both proliferation and migration of
RPASMC at 0.5 and 1 mM when compared to control cells
(Fig. 6a and b). To determine whether ET-1 released from
RPAFs was responsible for RPASMC phenotype changes,
RPASMC cells were incubated in RPAF conditioned media
from normoxic or hypoxic culture with or without the add-
ition of the endothelin receptor antagonist, Ambrisentan. As
previously shown, only the addition of hypoxic CM resulted
in increased RPASMC proliferation; however, the addition
of Ambrisentan prevented the increase in proliferation
(Fig. 6c). Migration was also investigated using scratch
assay (Fig. 6d), as before hypoxic condition media was the
only media which resulted in almost complete gap closure,
the addition of Ambrisentan prevented this migratory
response (Fig. 6e).
Discussion
PAH is a debilitating disease with poor survival rates and,
whilst life-prolonging, current PAH treatments do little to
address the underlying cellular and molecular changes in the
heart or the vasculature. Our group has previously high-
lighted the importance of MAPK signalling, particularly
through p38 MAPK, in experimental models of PAH22;
however, the apical MAP3K responsible for these changes
has, until recently, been poorly characterised in this disease.
The recent study by Budas et al. was the first to describe a
pathological role of the MAP3K ASK1 in maladaptive
remodelling of the pulmonary vasculature and RV support-
ing rationale for ASK1 inhibition as a novel therapeutic
strategy for PAH.29 Whilst Budas and colleagues highlight
a role of ASK1 in disease pathogenesis and discussed pos-
sible cellular mechanisms involved in cardiac fibrogenesis,
less is known about the role ASK1 plays in pulmonary vas-
cular remodelling. The results of the presented study not
only support the preclinical findings of Budas et al. but
also address the underlying cellular mechanisms.
The present study investigates ASK1 inhibition in the
SuHx in vivo model where PAH occurs as a result of vas-
cular endothelial growth factor (VEGF) receptor blockade
concurrently with chronic hypoxia resulting in precapillary
arterial occlusion.34 Where our study differs from the previ-
ous study29 is that we use the now more commonly used
model of a single dose of 20mg/kg SU5416 at the com-
mencement of hypoxic phase followed by three weeks nor-
moxia prior to treatment compared to 200mg/kg and three
weeks hypoxia only. While both models have been used
extensively in PAH study, lower dose SU5416 is known to
be sufficient for PAH-like features which worsen in nor-
moxia, developing into complex vascular lesions.35 We con-
firm that disease was established after five weeks (online
Supplemental Fig. 2) and as such we believe this a more
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Fig. 4. ASK1 inhibition prevents hypoxia-induced increases in protein abundance in rat pulmonary artery fibroblasts (RPAFs) derived from wild-
type animals. RPAF were exposed to either normoxic or hypoxic culture conditions for 24 h in the presence or absence of 1% serum (þserum),
with or without the ASK1 inhibitor GS-444217 (þGS), protein abundance was determined in the resulting cell lysate by Western blot analysis. (a)
Typical Western blots of the hypoxia-induced transcription factor HIF-1a, phosphorylated (p) ASK1, MKK3/6, MKK4, JNK and p38 MAPK. Total
(t) p38 MAPK is used here as a house-keeping protein and loading control for densitometry of Western blots to determine protein relative
abundance. Protein abundance was graphically represented as bar chart (b) HIF-1a, (c) pASK1, (d) pERK1/2, (e) pp 38 MAPK, (f) pMKK3/6 and (g)
pJNK. n¼ 3 (biological replicates), displayed as bar chart as mean SEM for ease of interpretation. All stats are vs normoxic controls analysed by
one-way ANOVA and Bonferroni’s multiple comparison test. *p 0.05 and **p 0.01. Cell culture conditioned media analysis was also carried
out to quantify the levels of (h) soluble intracellular adhesion molecule 1 (sICAM-1), (i) tissue inhibitor of metalloproteinases (TIMP1) and (j)
endothelin-1 (ET-1). Quantification data are n¼ 5 per group for all plasma analyses and displayed as individual data points with error bars
representing mean SEM. Statistical analysis is by one-way ANOVA with Turkey’s post hoc analysis. *p 0.05 and **p 0.01.
SFM: serum free media; HIF-1a: hypoxia-inducible factor-1a; pASK1: phospho apoptosis signal-regulating kinase 1; pp 38 MAPK: phospho p38
mitogen-activated protein kinase.
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Fig. 5. Effects of ASK1 inhibition on hypoxia-induced rat pulmonary artery fibroblast and smooth muscle cell proliferation and migration.
Proliferation was determined by [3H] thymidine incorporation assay in rat pulmonary artery fibroblasts (RPAFs) and rat pulmonary artery smooth
muscle cells (RPASMCs). (a and b) Proliferation of RPAFs and RPASMCs (counts/min) was determined in cells exposed to either normoxic or
hypoxic culture conditions with or without the ASK1 inhibitor GS-444217 for 24 h. (c) RPASMC proliferation was determined in cells grown in
co-culture with RPAFs, groups investigated are RPASMC cultured in serum free media (SFM), those co-cultured with RPAFs in normoxic
conditions (Norm CC), those cultured with RPAFs in hypoxic conditions (Hyp CC) and those cultured with RPAFs in hypoxic conditions in the
presence of GS-444217 (Hyp CCþGS). (d) RPASMC proliferation determined in cells grown in the presence or absence of conditioned culture
media (CM-media used previously to culture RPAF cells in various culture conditions). Groups investigated are RPASMC cultured in serum free
media (SFM), those cultured with CM from normoxic RPAFs (Norm CM), those cultured with CM from hypoxic (Hyp CM) RPAFs and those
cultured in CM from hypoxic RPAFs in the presence of GS-444217 (Hyp CMþGS). Migration was determined by scratch closure assay in RPAFs
and RPASMCs. (e and f) Migration of RPAFs and RPASMCs (% reduction) was determined in cells exposed to either normoxic or hypoxic culture
conditions with or without the ASK1 inhibitor GS-444217 for 24 h. (g) RPASMC migration was determined in cells grown in co-culture with
RPAFs, groups investigated are RPASMC cultured in SFM, Norm CC, Hyp CC and Hyp CCþGS. (h) RPASMC migration was determined in cells
grown in the presence or absence of conditioned CM, groups investigated are RPASMC cultured SFM, Norm CM, Hyp CM and Hyp CmþGS.
Proliferation data are n¼ 4 and migration data are n¼ 3, all are displayed as individual data points with mean. Statistical analysis is by one-way
ANOVA and Tukey or Bonferroni multiple comparison test. *p 0.05, **p 0.01 and ***p 0.001.
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representative model to investigate disease reversal than
investigated previously29 where treatment began at the end
of hypoxic phase. Furthermore, there is also increasing
speculation that 200mg/kg of SU5416 may promote greater
apoptotic damage to cells, particularly ECs36 which may
make investigation of cellular processes more complex.
Here, as expected, many of the hallmarks of PAH were
observed in the SuHx animals; these include raised RVSP,
RV hypertrophy, cardiac fibrosis, vascular remodelling and
increased circulating levels of factors associated with disease
pathogenesis. The addition of GS-444217 reversed the
changes in many of these features.
It is known that the RV adapts structurally in PAH, with
hypertrophy triggered by pressure overload. In contrast to
previous findings,29 RV hypertrophy was sustained in the
present study despite a reduction observed in both RVSP
and pulmonary vascular remodelling. We believe that this
demonstrates that the ASK1 inhibitor has a primary effect
on the lung vasculature thus reducing RVSP. We speculate
that with a reduction in RV wall stress as a consequence of
reduced vascular remodelling, with time cardiac hypertro-
phy may also decrease. This theory is supported by a reduc-
tion in cardiomyocyte cross sectional area and a decrease in
plasma BNP, features which are ordinarily hallmarks of the
failing heart. BNP levels have been shown to correlate with
mPAP and PVR in patients and a fall in levels after therapy
is associated with improved survival.37 Budas et al. state that
ASK1 inhibition in their pulmonary artery banding (PAB)
mouse model has an intrinsic effect on the heart, shown
through a reduction in cardiac fibrosis. While not using a
heart-specific model such as the PAB model, we demon-
strate reduced cardiac collagen deposition in the
Fig. 6. Rat pulmonary artery smooth muscle cell (RPASMC) characteristics in the presence of endothelin-1 (ET-1) or endothelin receptor
antagonist (ERA) Ambrisentan. Rat pulmonary artery smooth muscle cell (RPASMC) was investigated in the presence of endothelin-1 (ET-1),
conditioned media from hypoxic or normoxic rat pulmonary artery fibroblast (RPAF) or the endothelin receptor antagonist (ERA) Ambrisentan.
RPASMC were observed for (a) proliferative response (determined by [3H] thymidine incorporation assay) or (b) migration (determined by
scratch closure assay) following the addition of increasing concentrations of ET-1. Further to this RPASMC (c) proliferation and migration (d and
e) were also investigated in the presence of conditioned media from normoxic or hypoxic RPAFs in the presence or absence of Ambrisentan. All
data are n¼ 3–7 biological replicates and displayed as individual with mean SEM. All stats are vs SFM and analysed by one-way ANOVA and
Tukey’s multiple comparisons test. **p 0.01 and ***p 0.001.
SFM: serum free media.
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SuHxþGS and as these hearts have reduced pp38 MAPK,
the cardiac effects may be MAPK mediated.
In our SuHx model, raised RVSP was accompanied by
pulmonary artery remodelling, which the ASK1 inhibitor
reversed, suggesting a direct action of ASK1 inhibition on
the vascular wall. It is known that vascular remodelling
observed in PAH involves changes in all three layers of
the vascular wall and we have previously demonstrated the
importance of the PAF in PAH22,38 where early activation,
differentiation and subsequent migration of fibroblasts is
important in vascular wall thickening.9 In the present
study, PAF were cultured from experimental animals, we
believe this to be the first time this in vivo to in vitro
approach with RPAF and the SuHx model has been
reported. SuHxþV cells displayed enhanced migration
and proliferation under normoxic culture conditions.
These cells also demonstrated enhanced pp38 MAPK abun-
dance supporting our previous findings that proliferative
and migratory response in RPAFs is mediated by MAPK
signalling.33,39 Further supporting a role of MAPK signal-
ling, SuHxþGS cells had reduced pp38 MAPK abundance,
migration and proliferation – the first time that a phenotypic
change attributed to MAPK signalling has been observed in
this cell type after isolation from experimental animals trea-
ted with MAPK inhibitor.
To investigate further the role of ASK1 in PAFs, we
utilised a hypoxic in vitro model of PH (described in detail
elsewhere33,40) in control PAF cells. In line with observa-
tions in cultured patient fibroblasts,41 hypoxia increased
ROS and lactate production (online Supplemental Fig. 3),
suggesting increased aerobic glycolysis. Hypoxia also caused
a rise in the activation (phosphorylation) of many of the
investigated MAPKs and HIF-1a, the ASK1 inhibitor pre-
vented phosphorylation of these proteins.
HIF-1 is a potent transcription factor which affects and
regulates the expression of dozens of genes involved in
homeostatic maintenance as oxygen concentrations
change.42 During normoxia, the HIF-1a subunit is
polyubiquitinated and targeted for degradation by proline-
hydroxylase-2 (PHD-2) and by von-Hippel-Lindau (VHL)-
ubiquitin ligase complexes.43 During hypoxia, the decline in
oxygen levels directly decreases the activity of the PHDs,
thereby preventing hydroxylation of the HIF-1a protein.44
The lack of hydroxylation inhibits pVHL from binding
to HIF-1a, allowing HIF-1a to be stabilised. More
recent understanding suggests that hydroxylases are not
the sole regulators of HIF-1 during hypoxia but that intra-
cellular signalling pathways are also required for activation
during hypoxia. For example, it has been shown that
MAPK and other kinase pathways are involved. While the
upstream activators of these kinases have yet to be fully
identified, ROS generated during hypoxia may be a
candidate.45
Activation of HIF-1a is a multi-step process and emer-
ging evidence has shown that this process involves the phos-
phorylation of its regulatory/inhibitory domain by p38
MAPK and other kinase signalling pathways.42,45,46 p38
MAPK, activated by ASK1, has been shown to phosphor-
ylate and therefore support ischemic and LPS-dependent
accumulation of HIF-1a47–49 pharmacological inhibition
of p38a MAPK has also been shown to decrease hypoxic
activation of HIF-1.50 In accordance with these findings, we
demonstrate that ASK1 is selectively required for the acti-
vation of p38 MAPK in the hypoxia model of PH and that
p38 MAPK plays a contributory role to the hypoxia-driven
activation of HIF-1a by phosphorylation. HIF-1a is
involved in proliferation, glycolytic pathways and nitric
oxide synthesis, all of which were found to be altered here
and prevented by the addition of the ASK1 inhibitor (online
Supplemental Fig. 3).
Hypoxia significantly increases RPAF but not RPASMC
proliferation and migration when cultured alone; however,
enhanced proliferation and migration were observed in
RPASMCs both in co-culture and in the presence of
RPAF Hyp CM. ASK1 inhibition prevented both RPAF
and RPAF-mediated RPASMC-RPAF co-cultured pheno-
typic changes suggesting that not only are fibroblasts
undergoing phenotypic changes but hypoxia sensing is
being relayed to the adjacent RPASMCs. Fibroblasts have
been shown to exert significant paracrine effects on other
cells, producing a wide array of cytokines, growth factors
and inflammatory mediators.38
Whilst not the only mitogenic factor responsible for pul-
monary vascular remodelling, ET-1 is one of the strongest
expressed in our model. ET-1 has previously been implicated
in the pathogenesis of PAH,51 it is known to be upregulated
in PAH patients, and levels have been shown to correlate
negatively with PVR and mPAP.52 Inhibition of ET-1 signal-
ling has been shown to significantly attenuate the oxidative
stress associated with PAH.53 A rise in ET-1 was detected in
PAF CM in our in vitro model of PH; interestingly when the
CM of the in vivo to in vitro cells was investigated, a signifi-
cant rise in ET-1 was also noted in SuHxþV compared to
the other groups investigated. The synthesis and release of
ET-1 from PAF has previously been linked with the regula-
tion of other cell types in neovascularisation and angiogen-
esis,54 for example ET-1 promotes vasoconstriction through
a direct effect on SMC membrane-bound ET-1 receptors.55
Confirming a role of ET-1 in this model, RPAF-stimulated
PASMCs migration and proliferation could be blocked by a
selective endothelin A receptor (ETA) receptor antagonist
(Ambrisentan). As ASK1 inhibition prevents this response,
increased ET-1 transcription from RPAFs may be a result of
the MAPK signalling pathways and HIF-1a acting as a tran-
scription factor.56
ET-1 also induces fibroblast differentiation, ECM synthe-
sis and fibrosis,57,58 all features noted in our study. ET-1
may have autocrine effects on RPAFS increasing its own
expression via membrane-bound ETA receptors. As ASK1
inhibition prevents the release of ET-1 into CM, this sug-
gests that ET-1 may be driving some of the phenotypic
changes in the RPAFs too.
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ET-1 may also be responsible for some of the remodelling
features (TIMP-1 expression and collagen deposition) in the
heart observed here. PAH is characterised by increased
ECM production contributing to the remodelling of the
adventitia.59 Proteolytic enzymes such as matrix metallopro-
teinases (MMPs) are involved in collagen degradation.59
The activities of MMPs are counteracted by TIMPs which
control the overall turnover of matrix proteins. In our study,
we observed increased TIMP-1 which inhibits collagenases,
stromelysin and gelatinases.60 TIMP-1 levels were increased
in both our cellular and animal models and reduced by the
addition of GS-444217 suggesting that TIMP-1 is controlled
by ASK1 activity.
The disparity between the in vivo, in vitro and clinical data
highlights the challenges in translating pre-clinical findings
into clinical success. While the pre-clinical models recapitu-
late many of the features of PAH pathogenesis, they do not
truly replicate the complexity of the disease in the patient
population; rodent and cellular studies represent a homo-
genous study population, whereas it is known that PAH
patients display differing genetic backgrounds, co-morbid-
ities and are often currently on vasodilator therapies which
may influence their ability to respond to novel treat-
ments.61–63 It is also well recognised that inter-individual
differences mean that patients can respond differently to
the same PAH treatment,64 a point highlighted by the
large standard deviation observed within each group in the
ARROW study.65
In the ARROW study, patients were eligible with idio-
pathic or heritable PAH; drug- and toxin-induced PAH or
PAH associated with connective tissue disease, HIV infec-
tion or congenital heart defects; of these idiopathic and
heritable PAH represented 56% and 15% of study partici-
pants, respectively.31 It is likely that the causative molecu-
lar and cellular pathways contributing to disease
progression differ within the patient population and it
may be that any therapeutic effect noted was diluted by
larger groups with limited efficacy. For example, our study
highlights changes in ET-1, and while ET-1 inhibition
shows some prognostic success in some patients, it is
found to vary in efficacy between some subgroups of
patients, for example those patients who have PAH asso-
ciated with congenital heart disease.66 Furthermore, there
are ET-1 pathway polymorphisms and as such treatment
responses vary in patients with PAH. A number of con-
founding factors such as African ethnicity, male sex and
older age are associated with a raised plasma ET-1; while
angiotensin-converting enzyme inhibitors, statins, b-block-
ers and vasodilators reduce the level of ET-1 in plasma.67
As ASK1 inhibition displays significant success in rodent
models,29 it may offer a more viable treatment in more
specific patient phenotypes; here, post hoc analysis of
patient data may provide greater understanding.
Whilst combination therapy is an important treatment
strategy for PAH, it should be highlighted that in our in
vivo study, ASK1 was the sole treatment, in the ARROW
study, 92% of patients were on combination therapy and
all were symptomatic despite therapy. It is unclear
whether combined therapy could have resulted in additive,
synergistic or antagonistic interactions with the ASK1
inhibitor leading to differences in efficacy, possibly explain-
ing the lack of response in patients compared to the rodent
studies.
The ARROW study duration was 24 weeks, and whilst
clinical trials assessing vasoactive changes with vasodilator
treatments can be observed in as little as four months of
treatment, this may not have been significantly long
enough to have an impact on PVR using an anti-prolifera-
tive/anti-fibrotic treatment. While positive correction in
mPAP was noted in our study, the duration was perhaps
not long enough to produce reversal in RVH as noted in the
prevention study.29
Finally, whilst the primary endpoint was not achieved in
the ARROW study, it should be highlighted that a correl-
ation of reduced PVR was seen in the higher dose groups
(6mg and 18mg); although, this data was confounded by an
increase from baseline vascular resistance in the low-dose
group.65 It should also be highlighted that there were no
significant adverse events seen in the treatment group
and the number of participants that had an improved
WHO functional class was notably higher in the treatment
groups (14–19%) when compared to the placebo
group (3%).65
Conclusion
ASK1-dependent stress-signalling pathways are known
to be critical in the remodelling processes observed
in PAH. Here, the selective ASK1 inhibitor (GS-444217)
reduced lung vascular remodelling and subsequently
RVSP in a SuHx model of PH. Furthermore, ASK1
inhibition prevented chronic hypoxia-induced prolifer-
ation and migration of RPAFs in vitro and prevented
hypoxia-induced RPAF cytokine production and mitogenic
signalling to adjacent RPASMCS, a feature which is in
keeping with the multi-cellular vascular changes of PAH
pathogenesis. The beneficial effects of GS-444217 appear
to be as result of reduced fibroblast activation-migration,
proliferation and expression of mitogenic factors such
as ET-1.
The data presented here demonstrates the mechanistic
role of ASK1 in remodelling associated with PAH and high-
lights the potential of ASK1 inhibition as a valid anti-remo-
delling treatment for PAH due to its positive effects on the
PAF; however, it is clear that further investigation into why
such compelling pre-clinical evidence has not been replicated
in patient studies.
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